Papers by Sharon Cohen · AgingResearch.News

Drugs1 Sep
Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes
Trial in peopleInterventions
Paper
AAIC 2025 Abstract26 Dec
Subcutaneous Lecanemab: Potential Benefits and Place in Therapy
Trial in peopleInterventions
Paper
AAIC 2025 Abstract25 Dec
Multiple‐Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid‐Beta Precursor Protein for Alzheimer’s Disease
Trial in peopleInterventions
Paper
AAIC 2025 Abstract23 Dec
Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 Homozygotes
Trial in peopleInterventions
Paper

AAIC 2025 Abstract23 Dec
Valiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78‐Week APOLLOE4 Phase 3 Trial
Trial in peopleInterventions
Paper
AAIC 2025 Abstract23 Dec
Safety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD
Trial in peopleInterventions
Paper
AAIC 2025 Abstract23 Dec
MINDFuL: a Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Clinical Trial of XPro1595 for Patients with Early Alzheimer's Disease and Biomarkers of Inflammation
Trial in peopleInterventions
Paper
AAIC 2025 Abstract23 Dec
Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results
Computational studyInterventions
Paper